<?xml version='1.0' encoding='utf-8'?>
<document id="27600106"><sentence text="In vitro inhibition of UGT1A3, UGT1A4 by ursolic acid and oleanolic acid and drug-drug interaction risk prediction."><entity charOffset="41-53" id="DDI-PubMed.27600106.s1.e0" text="ursolic acid" /><entity charOffset="58-72" id="DDI-PubMed.27600106.s1.e1" text="oleanolic acid" /><pair ddi="false" e1="DDI-PubMed.27600106.s1.e0" e2="DDI-PubMed.27600106.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s1.e0" e2="DDI-PubMed.27600106.s1.e1" /></sentence><sentence text="1" /><sentence text=" Ursolic acid (UA) and oleanolic acid (OA) may have important activity relevant to health and disease prevention"><entity charOffset="1-13" id="DDI-PubMed.27600106.s3.e0" text="Ursolic acid" /><entity charOffset="15-17" id="DDI-PubMed.27600106.s3.e1" text="UA" /><entity charOffset="23-37" id="DDI-PubMed.27600106.s3.e2" text="oleanolic acid" /><entity charOffset="39-41" id="DDI-PubMed.27600106.s3.e3" text="OA" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e0" e2="DDI-PubMed.27600106.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e0" e2="DDI-PubMed.27600106.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e0" e2="DDI-PubMed.27600106.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e0" e2="DDI-PubMed.27600106.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e1" e2="DDI-PubMed.27600106.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e1" e2="DDI-PubMed.27600106.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e1" e2="DDI-PubMed.27600106.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e2" e2="DDI-PubMed.27600106.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27600106.s3.e2" e2="DDI-PubMed.27600106.s3.e3" /></sentence><sentence text=" Thus, we studied the activity of UA and OA on UDP-glucuronosyltransferases (UGTs) and used trifluoperazine as a probe substrate to test UGT1A4 activity"><entity charOffset="92-107" id="DDI-PubMed.27600106.s4.e0" text="trifluoperazine" /><entity charOffset="34-48" id="DDI-PubMed.27600106.s4.e1" text="UA" /><entity charOffset="41-55" id="DDI-PubMed.27600106.s4.e2" text="OA" /><pair ddi="false" e1="DDI-PubMed.27600106.s4.e1" e2="DDI-PubMed.27600106.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27600106.s4.e1" e2="DDI-PubMed.27600106.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27600106.s4.e1" e2="DDI-PubMed.27600106.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s4.e2" e2="DDI-PubMed.27600106.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27600106.s4.e2" e2="DDI-PubMed.27600106.s4.e0" /></sentence><sentence text=" Recombinant UGT-catalyzed 4-methylumbelliferone (4-MU) glucuronidation was used as a probe reaction for other UGT isoforms"><entity charOffset="27-48" id="DDI-PubMed.27600106.s5.e0" text="4-methylumbelliferone" /><entity charOffset="50-54" id="DDI-PubMed.27600106.s5.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.27600106.s5.e0" e2="DDI-PubMed.27600106.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s5.e0" e2="DDI-PubMed.27600106.s5.e1" /></sentence><sentence text=" 2" /><sentence text=" UA and OA inhibited UGT1A3 and UGT1A4 activity but did not inhibit other tested UGT isoforms"><entity charOffset="1-4" id="DDI-PubMed.27600106.s7.e0" text="UA" /><entity charOffset="8-11" id="DDI-PubMed.27600106.s7.e1" text="OA" /><pair ddi="false" e1="DDI-PubMed.27600106.s7.e0" e2="DDI-PubMed.27600106.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s7.e0" e2="DDI-PubMed.27600106.s7.e1" /></sentence><sentence text=" 3" /><sentence text=" UA-mediated inhibition of UGT1A3 catalyzed 4-MU-β-d-glucuronidation was via competitive inhibition (IC50 0"><entity charOffset="1-2" id="DDI-PubMed.27600106.s9.e0" text="UA" /><entity charOffset="44-45" id="DDI-PubMed.27600106.s9.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.27600106.s9.e0" e2="DDI-PubMed.27600106.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s9.e0" e2="DDI-PubMed.27600106.s9.e1" /></sentence><sentence text="391 ± 0" /><sentence text="013 μM; Ki 0" /><sentence text="185 ± 0" /><sentence text="015 μM)" /><sentence text=" UA also competitively inhibited UGT1A4-mediated trifluoperazine-N-glucuronidation (IC50 2"><entity charOffset="1-4" id="DDI-PubMed.27600106.s14.e0" text="UA" /></sentence><sentence text="651 ± 0" /><sentence text="201 μM; Ki 1" /><sentence text="334 ± 0" /><sentence text="146 μM)" /><sentence text=" 4" /><sentence text=" OA offered mixed inhibition of UGT1A3-mediated 4-MU-β-d-glucuronidation (IC50 0"><entity charOffset="1-2" id="DDI-PubMed.27600106.s20.e0" text="OA" /><entity charOffset="48-49" id="DDI-PubMed.27600106.s20.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.27600106.s20.e0" e2="DDI-PubMed.27600106.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27600106.s20.e0" e2="DDI-PubMed.27600106.s20.e1" /></sentence><sentence text="336 ± 0" /><sentence text="013 μM; Ki 0" /><sentence text="176 ± 0" /><sentence text="007 μM) and competitively inhibited UGT1A4-mediated trifluoperazine-N-glucuronidation (IC50 5" /><sentence text="468 ± 0" /><sentence text="697 μM; Ki 6" /><sentence text="298 ± 0" /><sentence text="891 μM)" /><sentence text=" 5" /><sentence text=" Co-administering OA or UA with drugs or products that are substrates of UGT1A3 or UGT1A4 may produce drug-mediated side effects"><entity charOffset="24-27" id="DDI-PubMed.27600106.s30.e0" text="UA" /><entity charOffset="18-21" id="DDI-PubMed.27600106.s30.e1" text="OA" /><pair ddi="false" e1="DDI-PubMed.27600106.s30.e1" e2="DDI-PubMed.27600106.s30.e1" /><pair ddi="false" e1="DDI-PubMed.27600106.s30.e1" e2="DDI-PubMed.27600106.s30.e0" /></sentence><sentence text="" /></document>